NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the August 2013 NCCN Trends™ Survey, which focused on Granulocyte-Colony Stimulating Factor. This survey was sent to U.S. and International users of NCCN.org.

DEMOGRAPHICS

Distribution of Respondent Types (n = 1,446)

- 64% Physician/Surgeon/Oncologist
- 17% Nurse/Oncology Nurse or Clinical Nurse Specialist
- 11% Pharmacist
- 5% Physician Assistant or Nurse Practitioner
- 3% Other Clinician

Note: Percentages may not total 100 because of rounding.

© National Comprehensive Cancer Network, Inc. 2013, All Rights Reserved. For Personal Use Only. This report may not be reproduced or distributed beyond personal use in any form without the express written permission of NCCN.
Q1. Do you treat patients with G-CSF? (n = 1,446)

- Yes: 88%
- No: 12%
Q2. What percentage of patients in your practice/institution who require G-CSF treatment have access to this treatment? (n = 834)

Results: August 2013
GRANULOCYTE-COLONY STIMULATING FACTOR

- 100%: 49%
- 90-99%: 16%
- 80-89%: 8%
- 70-79%: 5%
- 60-69%: 5%
- 50-59%: 5%
- <50%: 13%
Q3. What is the primary reason that some patients in your practice/institution do not have G-CSF treatment? (Please select one response only) (n = 629)

- Cost / insurance coverage: 65%
- Difficulty obtaining G-CSF products: 6%
- Other: 30%
Q4. Please indicate which combination of percent ranges most accurately reflects the ratio of patients who are treated with a short-acting G-CSF agent in your practice/institution vs. patients treated with a long-acting G-CSF agent in your practice/institution. (n = 1,162)

Results: August 2013

**GRANULOCYTE-COLONY STIMULATING FACTOR**

<table>
<thead>
<tr>
<th>Combination</th>
<th>Percentage of Respondents</th>
</tr>
</thead>
<tbody>
<tr>
<td>100% short-acting / 0% long-acting</td>
<td>21%</td>
</tr>
<tr>
<td>80-99% short-acting / 1-20% long-acting</td>
<td>24%</td>
</tr>
<tr>
<td>60-79% short-acting / 21-40% long-acting</td>
<td>14%</td>
</tr>
<tr>
<td>40-59% short-acting / 41-60% long-acting</td>
<td>11%</td>
</tr>
<tr>
<td>20-39% short-acting / 61-80% long-acting</td>
<td>13%</td>
</tr>
<tr>
<td>1-19% short-acting / 81-99% long-acting</td>
<td>15%</td>
</tr>
<tr>
<td>0% short-acting / 100% long-acting</td>
<td>3%</td>
</tr>
</tbody>
</table>
Q5. What is the primary factor impacting the decision for the type of G-CSF agent (short-acting vs. long-acting) that a patient ultimately receives in your practice/institution? (Please select one response only) (n = 1,141)

Results: August 2013
GRANULOCYTE-COLONY STIMULATING FACTOR

- Ease of use: 17%
- Familiarity with the product: 9%
- Safety: 4%
- Efficacy: 12%
- Cost / Insurance coverage: 30%
- Dosing Requirements: 18%
- Other: 12%
Q6. Please indicate which combination of percent ranges most accurately reflects the ratio of patients in your practice/institution who receive their G-CSF therapy at your facility vs. those who administer their G-CSF at home (via self-injection or with the help of a caregiver). (n = 1,124)

Results: August 2013

GRANULOCYTE-COLONY STIMULATING FACTOR

<table>
<thead>
<tr>
<th>Percentage of Respondents</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>100% at facility / 0% at home</td>
<td>22%</td>
</tr>
<tr>
<td>80-99% at facility / 1-20% at home</td>
<td>26%</td>
</tr>
<tr>
<td>60-79% at facility / 21-40% at home</td>
<td>11%</td>
</tr>
<tr>
<td>40-59% at facility / 41-60% at home</td>
<td>11%</td>
</tr>
<tr>
<td>20-39% at facility / 61-80% at home</td>
<td>11%</td>
</tr>
<tr>
<td>1-19% at facility / 81-99% at home</td>
<td>15%</td>
</tr>
<tr>
<td>0% at facility / 100% at home</td>
<td>4%</td>
</tr>
</tbody>
</table>
Q7. Please indicate which combination of percent ranges most accurately reflects the ratio of patients administering their G-CSF therapy at home using traditional vial and syringe vs. those administering their G-CSF therapy at home using an auto-inject device. (n = 834)

Results: August 2013
GRANULOCYTE-COLONY STIMULATING FACTOR

100% vial and syringe / 0% auto-inject device: 29%
80-99% vial and syringe / 1-20% auto-inject device: 12%
60-79% vial and syringe / 21-40% auto-inject device: 5%
40-59% vial and syringe / 41-60% auto-inject device: 7%
20-39% vial and syringe / 61-80% auto-inject device: 5%
1-19% vial and syringe / 81-99% auto-inject device: 15%
0% vial and syringe / 100% auto-inject device: 26%
NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an NCCN Trends™ survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Senior Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world’s leading cancer centers, is dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

National Comprehensive Cancer Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.org/patients - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.